Because of the potential benefit of ruxolitinib in CSF3R T618I mutated myeloid neoplasms [25], the patient was commenced with an off-label prescription of ruxolitinib with a dose of 10 mg twice daily (day 0). Here, CSF3R is linked to myeloid neoplasm.